Episode 319 -- Deep Dive into SCG Plastics' $20 Million Settlement with OFAC for Violations of the Iran Sanctions Program
Joint Venture Basics for Large and Small Contractors
Bidding for Major Contracts? Compliance Requirements You Should Prepare for Now
Marriages don't last forever: How to terminate a Joint Venture - and come out of it relatively unscathed. Podcast episode 2
Marriages don't last forever - When Joint Ventures go wrong. Podcast episode 1
Construction Webinar Series: Building Compliance: Construction Industry Concerns Under FCA
Ashley Coselli and Daniel Wendt on Difficult Anti-Corruption Due Diligence Projects
Teeming with Teaming Agreements: Navigating Strategic Alliances in the Federal Marketplace
CIO-SP4 Is Ready To Launch: Is Your Business Equipped to Compete?
Roadmap to Joint Venture Agreements: Legal and Accounting Considerations
M&A Webinar - Trendspotting: The Rise of the Atypical Deal
SBA’s Final Rule on SBA’s MP Program, Joint Ventures, Affiliation and 8(a) Regulations
SBA’s Final Rule on Mentor-Protégé Programs: Key Changes for Government Contractors
Growth Strategies for Small Businesses Moving to Mid-Tier
Litigating During COVID: What You Need to Know
Shoot for the STARS: Q&A with SBA’s John Klein on GSA's 8(a) STARS III RFP
Williams Mullen's COVID-19 Comeback Plan: Selling Products and Services to the Federal Government
Day 18 of One Month to More Effective Compliance for Business Ventures-Financial Review of Your Business Venture Partner
Day 15 of One Month to More Effective Compliance for Business Ventures- Tying It All Together for Joint Ventures
Day 14 of One Month to More Effective Compliance for Business Ventures-Auditing Joint Ventures
On July 26, Prestige Biopharma Limited (“Prestige”) announced a partnership with Intas Pharmaceuticals Limited (“Intas”) and its affiliate Accord Healthcare to commercialize Prestige’s bevacizumab, HD204, a proposed...more
On Monday, Hikma announced a partnership with Celltrion to market YUFLYMA (CT-P17) in the Middle East and North Africa. CT-P17 is a high-concentration, low-volume and citrate-free adalimumab biosimilar, indicated for the...more
Eris Lifesciences (“Eris”) announced its joint venture with Mumbai-based MJ Biopharm Pvt Ltd. (“MJ”), Eris MJ Biopharm Ltd., focused on the marketing and distribution of insulins (including aspart, glargine and lispro),...more
Last week, PlantForm Corporation, PlantPraxis Biotecnologia and Bio-Manguinhos/Fiocruz announced that they are entering into a research and development agreement to develop pembrolizumab, a biosimilar of Keytruda®, for the...more
On February 9, 2021, Lannett Company announced that it had added a new co-development agreement for biosimilar insulin aspart with its strategic alliance partners within the HEC Group of Companies. Insulin aspart, currently...more
Biocon Biologics, a subsidiary of Biocon, announced today that it has signed an agreement with Clinton Health Access Initiative (CHAI) to develop advanced cancer therapies for patients in 25 countries in Africa and 5...more
On January 13, 2021, EVOQ announced a license and collaboration agreement with Amgen for the development of new drugs for autoimmune disorders. According to the press release, Amgen and EVOQ will collaborate on preclinical...more
On September 19, 2020, Lotus Pharmaceutical Co., Ltd. (“Lotus”) and Chong Kun Dang Pharmaceutical Corp. (“CKD”) announced that they have entered into a commercialization agreement in connection with CKD’s biosimilar...more
Last week, BeiGene and Bio-Thera Solutions announced that the companies had entered into a license, distribution, and supply agreement for BAT1706, Biothera’s Avastin® (bevacizumab) biosimilar, in China. According to the...more
Teva and Celltrion Healthcare announced today the U.S. launch of TRUXIMA® (rituximab-abbs) for rheumatoid arthritis (RA). TRUXIMA®, which originally launched in November 2019, is now approved to treat RA, non-Hodgkin lymphoma...more
Multiple biosimilar developers recently released statements regarding potential regulatory delays facing their biosimilars or follow-on biologics. ...more
Last week, Almirall signed an agreement with WuXi Biologics to collaborate on multiple bispecific antibodies targeting dermatology conditions, including atopic dermatitis. Almirall’s press release indicated that, “[u]nder the...more
Today, XBrane Biopharma and STADA Arzneimittel announced that they have entered into a co-development agreement for Xlucane, a proposed biosimilar of Lucentis® (ranibizumab), in which the companies will equally contribute and...more
Last week, Sandoz announced a new collaboration with Asian biopharmaceutical company Biocon to “to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide. Under the terms...more
As we’ve posted here, Biocon and Mylan are jointly developing a portfolio of biosimilars, and they have filed applications for marketing authorization in the European Union for three biosimilar products: Fulphila...more
Lanka Business News is reporting that Celltrion and George Steuart Health have teamed up to launch Remsima (infliximab) in Sri Lanka...more
As we previously reported, Amgen and Allergan are currently collaborating on four oncology biosimilars, including an Avastin® (bevacizumab) biosimilar, ABP 215. Yesterday, the companies announced the submission of a...more
On October 19, Fujifilm Kyowa Kirin Biologics (a joint venture between Fujifilm and Kyowa Hakko Kirin), announced successful results in the global Phase 3 study of its Humira® (adalimumab) biosimilar candidate, FKB327. ...more
Samsung Bioepis – the joint venture between Samsung and Biogen Idec – has started a phase III clinical trial for a biosimilar version of Roche’s cancer drug Avastin (bevacizumab). Bevacizumab slows the growth of new blood...more